You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

IXIFI Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: IXIFI
High Confidence Patents:0
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for IXIFI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for IXIFI Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for IXIFI Derived from Patent Text Search

No patents found based on company disclosures

The Impact of Biosimilars on the Biologic Drug Market: A Case Study of IXIFI

Introduction

The biologic drug market has undergone significant changes with the advent of biosimilars, which are biological products that are highly similar to and interchangeable with an already approved biological product. One such biologic drug that has faced the impact of biosimilars is IXIFI (infliximab-qbtx), a treatment for various autoimmune diseases. This article delves into the market dynamics and financial trajectory of IXIFI in the context of biosimilar competition.

Biologics and Biosimilars: An Overview

Biologics are complex, large-molecule drugs that have become a significant portion of the pharmaceutical market. They treat a range of chronic conditions, including autoimmune diseases, cancer, and diabetes. Biosimilars, on the other hand, are designed to be highly similar to these biologics, offering a more affordable alternative without compromising on efficacy and safety[3].

Market Dynamics of Biologics

Biologics have seen substantial growth over the past few years, with their market share increasing from 30% in 2014 to 42% in 2018. This growth is driven by their effectiveness in treating complex diseases and the expanding R&D pipeline in this area[3].

The Role of IXIFI in the Biologic Market

IXIFI is a biosimilar of Remicade (infliximab), which is used to treat conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. As a biosimilar, IXIFI aims to provide a cost-effective alternative to the original biologic, Remicade.

Impact of Biosimilars on IXIFI

Market Share and Adoption

The introduction of biosimilars like IXIFI has significantly altered the market dynamics for biologics. For instance, the biosimilar market share for infliximab, the reference product for IXIFI, has reached 54% as of Q3 2023. This rapid adoption is driven by the lower prices of biosimilars, which can reduce the average sales price (ASP) by up to 73% compared to the original biologic[4].

Price Erosion

Biosimilars have led to substantial price decreases in the biologic market. The ASP of infliximab biosimilars, including IXIFI, has declined by 70% to $236 as of Q1 2024. This price erosion is a result of increased competition and the launch of unbranded biosimilars, which further accelerates market share gains for biosimilars[4].

Financial Implications

The financial impact of biosimilars on the original biologics is significant. Companies like Janssen, the manufacturer of Remicade, have seen revenue declines due to biosimilar competition. For example, the launch of biosimilars for Remicade led to a decline in Pfizer's revenues from Enbrel in developed Europe markets, highlighting the financial implications of biosimilar entry[2].

Competitive Landscape

The competitive landscape for biologics and biosimilars is complex and dynamic. The market for biosimilars is often compared to the generics market for small molecules, where competition leads to lower prices and increased market share for the generic or biosimilar product. However, the biosimilar market faces unique challenges, including higher development costs and regulatory hurdles[1].

Therapeutic Areas and Market Share

Biosimilars are penetrating various therapeutic areas, including immunology, oncology, and endocrinology. In the immunology segment, biosimilars like IXIFI have achieved significant market share, particularly after the third year post-launch. For instance, the infliximab biosimilar market began to accelerate in year three, reaching a market share of 54% by Q3 2023[4].

Regulatory Environment

The regulatory environment plays a crucial role in the approval and launch of biosimilars. As of January 2024, the FDA has approved 45 biosimilars across 14 unique biological molecules. The approval process for biosimilars involves demonstrating biosimilarity to the reference product, which includes clinical trials and analytical studies[4].

Financial Guidance and Projections

Companies affected by biosimilar competition often adjust their financial guidance accordingly. For example, Pfizer anticipated a $2 billion impact from loss of exclusivity (LOE) in 2018, which was significantly lower than in previous years but still a notable factor in their financial projections. The ongoing competition from biosimilars is expected to continue influencing financial guidance for pharmaceutical companies[2].

R&D Pipeline and Innovation

Despite the challenges posed by biosimilars, pharmaceutical companies continue to invest in their R&D pipelines. The growth in biologics and the potential for biosimilars have driven innovation, with many companies focusing on developing new biologics and biosimilars to stay competitive. This innovation is crucial for maintaining market share and generating new revenue streams[2].

Market Adoption and Price Trends

The adoption of biosimilars varies across different therapeutic areas. In supportive care, for example, biosimilars have achieved higher market shares compared to immunology and endocrinology. The price trends also vary, with some markets showing significant price decreases post-biosimilar launch, while others may experience slower price erosion[4].

Case Study: Infliximab Biosimilars

The infliximab biosimilars, including IXIFI, provide a clear example of how biosimilars can disrupt the market. After a slow start, the infliximab biosimilar market began to accelerate in year three, with the market share reaching 54% by Q3 2023. The launch of an unbranded infliximab by Janssen in Q4 2022 further accelerated price erosion, highlighting the competitive dynamics in this segment[4].

Key Takeaways

  • Market Share and Adoption: Biosimilars like IXIFI have significantly impacted the market share of original biologics, achieving up to 54% market share in some therapeutic areas.
  • Price Erosion: The introduction of biosimilars has led to substantial price decreases, with ASP reductions of up to 73%.
  • Financial Implications: Biosimilar competition has significant financial implications for pharmaceutical companies, leading to revenue declines and adjustments in financial guidance.
  • Regulatory Environment: The FDA has approved numerous biosimilars, and the regulatory environment continues to evolve to accommodate these products.
  • Innovation and R&D: Despite the challenges, pharmaceutical companies are continuing to innovate and invest in their R&D pipelines.

FAQs

What is IXIFI, and how does it fit into the biologic market?

IXIFI is a biosimilar of Remicade (infliximab), used to treat autoimmune diseases like rheumatoid arthritis and Crohn's disease. It offers a cost-effective alternative to the original biologic.

How have biosimilars impacted the market share of original biologics?

Biosimilars have significantly reduced the market share of original biologics, with some biosimilars achieving up to 54% market share within three years of launch.

What is the average price reduction seen with the introduction of biosimilars?

The average sales price (ASP) can decline by up to 73% following the launch of biosimilars.

How do pharmaceutical companies adjust to the financial impact of biosimilars?

Companies adjust their financial guidance to account for the revenue impact of biosimilar competition, which can include significant revenue declines.

What role does the FDA play in the approval of biosimilars?

The FDA approves biosimilars after they demonstrate biosimilarity to the reference product through clinical trials and analytical studies.

Sources

  1. How Biosimilars are Shaking Up the Pharmaceutical Landscape. Harvard Kennedy School.
  2. Q4 2017 Pfizer Inc Earnings Call. Pfizer Inc.
  3. Biologics Market Dynamics: Setting the Stage for Biosimilars. FTC.
  4. Biosimilar Market Report - SAMSUNG BIOEPIS. Samsung Bioepis.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.